Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XanaMIA-DR a Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Pharmacodynamics and Safety of Xanamem® in Healthy Elderly Volunteers

NCT04983368 is registered in ClinicalTrials.gov with Actinogen Medical as lead sponsor.

NCT NCT04983368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04983368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XanaMIA-DR a Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Pharmacodynamics and Safety of Xanamem® in Healthy Elderly Volunteers
Lead sponsor
Actinogen Medical
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2021
Completion date
February 11, 2022
Enrollment
107 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, mild cognitive impairment